Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT07146126 is registered in ClinicalTrials.gov with Prime Gene Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07146126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07146126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
Lead sponsor
Prime Gene Therapeutics Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 15, 2025
Completion date
July 30, 2026
Enrollment
600 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

sar, seasonal allergic rhinitis